Defining eligibility of FOLFIRINOX for first-line metastatic pancreatic adenocarcinoma (MPC) in the Province of British Columbia: a population-based retrospective …
MY Ho, HF Kennecke, DJ Renouf… - American journal of …, 2017 - journals.lww.com
Background: FOLFIRINOX is a first-line treatment option for patients with metastatic
pancreatic cancer (MPC) and is associated with improved survival yet significantly more
toxicities than standard gemcitabine. Our aim was to determine the proportion of patients
with MPC who would be eligible for FOLFIRINOX based upon the pivotal ACCORD study
criteria. Methods: Patients with confirmed MPC at the time of referral to the BC Cancer
Agency between 2004 and 2007 were identified from the Gastrointestinal Cancers …
pancreatic cancer (MPC) and is associated with improved survival yet significantly more
toxicities than standard gemcitabine. Our aim was to determine the proportion of patients
with MPC who would be eligible for FOLFIRINOX based upon the pivotal ACCORD study
criteria. Methods: Patients with confirmed MPC at the time of referral to the BC Cancer
Agency between 2004 and 2007 were identified from the Gastrointestinal Cancers …